The vaccine will offer protection against H5N1 and is projected to be effective against future viral mutations.

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

In just 3 years, the Influenza Vaccines Research and Development (R&D) Roadmap Initiative has demonstrated important ...

Influenza viruses like bird flu can mix and match their genomes, and this has played a role in at least three of the last ...

The H5N1 avian flu is circulating in cows and other mammals. Whether it will make a permanent leap to humans is another ...

This is the first time we’ve had access to an influenza genome from the 1918–1920 pandemic in Switzerland. It opens up new insights into the dynamics of how the virus adapt ...

Dysregulated myelopoiesis is identified as a driver of nutritionally acquired immunodeficiency that persists after refeeding and nutritional recovery, indicating exposure to food scarcity may be an ...